203 related articles for article (PubMed ID: 38456971)
1. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [
Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Mai EK; Hajiyianni M; Merz M; Raab MS; Jauch A; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2024 Mar; ():. PubMed ID: 38456971
[TBL] [Abstract][Full Text] [Related]
2. Application of an artificial intelligence-based tool in [
Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Jauch A; Hajiyianni M; John L; Weinhold N; Sauer S; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3697-3708. PubMed ID: 37493665
[TBL] [Abstract][Full Text] [Related]
3. Can physiologic colonic [
Sachpekidis C; Stein-Thoeringer CK; Kopp-Schneider A; Weru V; Dimitrakopoulou-Strauss A; Hassel JC
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3709-3722. PubMed ID: 37452874
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
7. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
10. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
12. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
13. Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma.
Fonti R; Pellegrino S; Catalano L; Pane F; Del Vecchio S; Pace L
Ann Hematol; 2020 Jan; 99(1):127-135. PubMed ID: 31776725
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of [
Sachpekidis C; Merz M; Raab MS; Bertsch U; Weru V; Kopp-Schneider A; Jauch A; Goldschmidt H; Dimitrakopoulou-Strauss A
EJNMMI Res; 2021 Oct; 11(1):100. PubMed ID: 34628525
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Role of 2-[
Albano D; Dondi F; Mazzoletti A; Bellini P; Rodella C; Bertagna F
Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943426
[TBL] [Abstract][Full Text] [Related]
16. Relation of whole-body metabolic tumor volume and total lesion glycolysis on fluorodeoxyglucose PET/computed tomography with clinical and laboratory parameters in newly diagnosed multiple myeloma.
Goksel S; Ilkkilic K; Bulbul O; Akdogan E
Nucl Med Commun; 2022 Oct; 43(10):1077-1083. PubMed ID: 36006402
[TBL] [Abstract][Full Text] [Related]
17. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
Chung HW; Lee KY; Kim HJ; Kim WS; So Y
J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
[TBL] [Abstract][Full Text] [Related]
18. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of the
Yang Y; Pan YQ; Wang M; Gu S; Bao W
Radiat Oncol; 2023 Dec; 18(1):196. PubMed ID: 38049843
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
